BioPharma Dive June 20, 2024
Researchers reported zero infections in the study group given Gilead’s lenacapavir, and recommended the company stop the Phase 3 trial early.
Dive Brief:
- Twice-yearly shots of a Gilead Sciences HIV drug were so effective at preventing infections in a large late-stage clinical trial that study monitors recommend the company stop testing early and offer the drug to all participants.
- The trial, called Purpose 1 and run in South Africa and Uganda, compared Gilead’s medicine lenacapavir to once-daily Truvada and background HIV infection rates among cisgender women. Lenacapavir proved superior to both, with zero HIV infections reported in the study group, Gilead said Thursday.
- Gilead hopes testing of twice-yearly lenacapavir will prove it an effective and more convenient preventive option...
Today's Sponsors
Today's Sponsor